Colorectal Cancer
Conditions
Keywords
rectal, low risk, moderate risk
Brief summary
The purpose of this study is to first determine the maximum tolerated dose of capecitabine given alone or in combination with valproic acid during preoperative short-course radiotherapy (Phase 1). The next part of the study (Phase 2)will explore whether the addition of valproic acid or the addition of capecitabine to short-course radiotherapy, before optimal radical surgery might increase the pathologic complete tumor regression rate in patients with low-moderate risk rectal cancer.
Interventions
DRUGValproic Acid
DRUGCapecitabine
RADIATIONpreoperative radiation therapy
25 Gy in 5 fractions over 1 week
Sponsors
National Cancer Institute, Naples
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
• Patients with histologically confirmed diagnosis of adenocarcinoma of rectum falling into one of the following categories: T2N0 located at \<2 cm from anal verge T2N1 or T3N0-N1, located at \>5 cm and \<12 cm from anal verge and infiltration of perirectal fat up to a distance of 1 mm from mesorectal fascia (MRF) evaluated by MRI. * Age ≥18 and ≤ 70 * ECOG Performance Status ≤1 * Effective contraception for both male and female patients if the risk of conception exist * Signed written informed consent
Exclusion criteria
* Any previous treatment for rectal cancer * Previous pelvic radiotherapy * Presence of metastatic disease * Recurrent rectal tumor * Patient with Familial Adenomatosis Polyposis (FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC) * History of inflammatory bowel disease or active disease * Any concurrent malignancy except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of cervix uteri. Patients with a previous malignancy but without evidence of disease for 5 years will be allowed to enter the trial. * Neutrophils \< 2000/mm3 or platelets \< 100.000/ mm3 or haemoglobin \<9 gr/dl. * Creatinine levels indicating renal clearance of \<50 ml/min * GOT and/or GPT \> 2.5 time the UNL and/or bilirubin \>1.5 time the upper-normal limits (UNL) * Significant cardiovascular comorbidity (e.g. myocardial infarction, superior vena cava \[SVC\] syndrome, patients with an ejection fraction of \<50%) or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia. * History of arrhythmia (multifocal premature ventricular contractions \[PVCs\], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. * Patients with long QT-syndrome or QTc interval duration \> 480 msec or concomitant medication with drugs prolonging QTc (see list in the appendix) * Known dihydropyrimidine dehydrogenase (DPD) deficiency * HIV positive patients * Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease. * Known or suspected hypersensitivity to any of the study drugs. * Patient who have had prior treatment with an HDAC inhibitor and patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid. * Concurrent uncontrolled medical conditions that might contraindicate study drugs. * Major surgical procedure, within 28 days prior to study treatment start. * Pregnant or lactating women. * Women of childbearing potential with either a positive or no pregnancy test at baseline (NB. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. * Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum tolerated dose of capecitabine, given alone or in combination with valproic acid | up to 3 weeks | Phase 1 primary objective |
| number of patients with complete pathological tumor regression | 8 weeks | evaluated at definitive surgery, planned 8 weeks after the end of radiotherapy, in all the study arms of Phase 2 |
Secondary
| Measure | Time frame |
|---|---|
| number of patients alive with disease progression | one year |
| changes in quality of life from baseline | up to 3 months |
| number of patients with pathologic complete response | 2 months |
| overall survival | 1 year |
Other
| Measure | Time frame | Description |
|---|---|---|
| evaluation of predictive factors | 2 months | description of predictive role of early tumor metabolic changes measured by PET scan |
| predictive and prognostic factors of tumor and circulating cells | 2 months | descriptive exploratory analyses |
Countries
Italy
Contacts
Primary ContactAntonio Avallone, M.D.
Backup ContactMaria Carmela Piccirillo, M.D.
Outcome results
None listed